Veraxa Biotech AG (VRXA)
Nasdaq: VRXA · Pharmaceutical Preparations · filing with the SEC since 2025
Who owns Veraxa Biotech AG
As filed with the SECHolders of 5% or more
4
Deck David Lukas holds 18% of Ordinary Shares, par value CHF 100/11325 per share, as its SCHEDULE 13D filed Jun 16, 2026 says.
Directors and officers
9
report now, of 9 people on the record since 2026. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Deck David Lukas
SCHEDULE 13D · filed Jun 16, 2026 · Ordinary Shares, par value CHF 100/11325 per share
Xlife Sciences AG
SCHEDULE 13D · filed Jun 15, 2026 · Ordinary Shares, par value CHF 100/11325 per share
European Molecular Biology Laboratory
SCHEDULE 13D · filed Jun 16, 2026 · Ordinary Shares, par value CHF 100/11325 per share
Schoeni Gilbert Edgar
SCHEDULE 13D · filed Jun 15, 2026 · Ordinary Shares, par value CHF 100/11325 per share
AQR Capital Management, LLC
SCHEDULE 13G/A · filed Aug 13, 2026 · Ordinary Shares, par value CHF 100/11,325 per share · reported falling below 5%
What VRXA reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Veraxa Biotech A G
An entity · legal entity · owns, named in the 20-F filed Jun 16, 2026
Veraxa Biotech Holding A G
An entity · legal entity · owns, named in the 20-F filed Jun 16, 2026
1 subsidiary in 1 country, from the list filed with the 20-F filed Jun 16, 2026.
Insider tradesForm 4
0sales
5purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$100,000bought, in dollars
Open-market trades on Form 4 from Oct 29, 2025 to Oct 29, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 29, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window4 of 9 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Gruninger Marc | director | 0 | $0 | 0 | 2 | $0 |
| Antz Christoph Rudiger | Chief Executive Officer | 0 | $0 | 0 | 1 | $0 |
| Ziegler Christoph Samuel | director | 0 | $0 | 0 | 1 | $0 |
| Baumann Oliver Rolf | director | 0 | $0 | 0 | 1 | $100,000 |